secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2021-11-09T23:59:59+00:00
Accession:  0001564590-21-055442
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Imara reports Q3 net loss $13.6M; tovinontrine Phase 2b interim data expected Q4 2021
--------------------------------------------------------------------------------

- Net loss $13.6M ($0.55/share) vs $12.4M ($0.72/share) in Q3 2020; cash & investments $102.8M.
- R&D expenses $10.4M; FY2021 R&D guidance $40-45M, G&A $12-13M; cash runway into Q1 2023.
- Phase 2b Ardent (SCD) and Forte (beta-thalassemia) trials fully enrolled; interim data Q4 2021, primary analysis Q1 2022.
- New pipeline asset IMR-261 (Nrf2 activator) acquired; preclinical data to be presented at ASH 2021.
- Hired cardiologist Dr. Toni Bransford to lead HFpEF Phase 2 trial of tovinontrine; trial expected to start 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000156459021055442/0001564590-21-055442-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000156459021055442/imra-8k_20211109.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-055442

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer